Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

Neuroblastoma is a predominantly p53 wild-type (wt) tumour and MDM2-p53 antagonists offer a novel therapeutic strategy for neuroblastoma patients. RG7388 (Roche) is currently undergoing early phase clinical evaluation in adults. This study assessed the efficacy of RG7388 as a single-agent and in com...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lindi, Rousseau, Raphaël F., Middleton, Steven A., Nichols, Gwen L., Newell, David R., Lunec, John, Tweddle, Deborah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496350/
https://www.ncbi.nlm.nih.gov/pubmed/25844600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496350/
https://www.ncbi.nlm.nih.gov/pubmed/25844600

Ejemplares similares